Secondary Logo

Journal Logo


Treatment 2.0

catalyzing the next phase of treatment, care and support

Duncombe, Chrisa; Ball, Andrewb; Passarelli, Carlosc; Hirnschall, Gottfriedd

Author Information
Current Opinion in HIV and AIDS: January 2013 - Volume 8 - Issue 1 - p 4-11
doi: 10.1097/COH.0b013e32835ba7ff
  • Free



The 2001 Abuja Declaration set funding targets for countries in the African Union to allocate at least 15% of their annual budget to improve the health sector, and urged donor countries to earmark 0.7% of their gross national product as official development assistance to developing countries [1]. After 11 years, the 2012 Health Financing Scorecard, released at the conference of ministers of finance and health on value for money, sustainability and accountability in the health sector in Tunisia indicates that only four African countries have met the 15% commitment [2,3▪]. Furthermore, major donors’ aid to developing countries fell by nearly 3% in 2011, the first drop since 1997 [4]. The Organization for Economic Cooperation and Development predicts that aid from donor countries will stagnate between 2012 and 2015 [5]. Despite flat and in some cases declining international assistance, global spending on HIV, at US$16.8 billion, was up 11% in 2011 over 2010 [6▪▪].

Health priorities are changing, with an increased focus on maternal and child health and noncommunicable diseases, and HIV services are being progressively integrated into broader health responses [7]. Although HIV incidence and prevalence are declining in most parts of the world, so is external funding for HIV [8]. Earlier initiation of treatment and better (but more expensive) drugs have added pressure to already stretched budgets of HIV programs, governments and donors. The use of antiretroviral drugs (ARVs), including antiretroviral therapy (ART), for HIV prevention and the early initiation and continued use of ART for pregnant women after delivery will further increase the numbers of people living with HIV who need treatment.

Box 1:
no caption available

Through the 2011 United Nations Political Declaration on HIV/AIDS, member states agreed on ten measurable targets towards the elimination of HIV/AIDS, three of them focusing on treatment-related issues: placing 15 million people on ART, the virtual elimination of new HIV infections in children and a 50% reduction in tuberculosis (TB) deaths among people living with HIV [9].


Against this background of changing global health priorities and funding, WHO and the UNAIDS Secretariat launched the Treatment 2.0 strategy in July 2010, with the aim of continuing the scale-up ART in an environment of global fiscal constraint. Treatment 2.0 provides leadership and technical guidance to reach universal and sustainable coverage of treatment while delivering value for money. Figure 1 summarizes the principles of Treatment 2.0. This global initiative promotes innovation and efficiency across five priority work areas: drugs, diagnostics, service delivery, community mobilization and cost reduction (Fig. 2). The framework describes how innovation and greater efficiency and effectiveness within each of the work areas will guide treatment scale-up over the next decade [7] and represents a long term, sustainable strategy for the prevention and treatment of HIV infection as a chronic manageable condition [10▪▪]. The Treatment 2.0 approach is aligned with the 2011–2015 UNAIDS Strategy and the WHO Global Health Sector Strategy on HIV/AIDS, 2011–2015 [11,12].

Principles of Treatment 2.0.
Treatment 2.0. Reproduced with permission from [10▪▪].


In July 2012, WHO released a discussion study ‘The strategic use of antiretrovirals to help end the HIV epidemic’ that summarizes the current WHO guidance on the use of ARVs, and highlights progress in implementation of the Treatment 2.0 strategy, the use of ART as prevention, and WHO's work on the next generation of normative guidelines [10▪▪]. With more than 8 million people on ART in low- and middle-income countries, coverage now stands at 54%, based on WHO's 2010 guidelines for ART initiation at a CD4 cell count 350 cells/μl or less [6▪▪]. Whereas an estimated fifteen million people currently are eligible for ART based on a CD4 cell count 350 cells/μl or less, 22 million could be eligible if ART were offered to all HIV-positive partners in serodiscordant couples, HIV-positive pregnant and breast-feeding women and key populations (MSM, IDU and sex workers) irrespective of CD4 cell count. (Fig. 3) In addition, raising the CD4 cell count threshold for ART initiation to 500 cells/μl and the scaling up treatment as prevention have the potential to increase the pool of people eligible for ART in low-income and middle-income countries to 32 million [10▪▪].

ART coverage in low-income and middle-income countries. Reproduced with permission from [13].


Goal: Effective, affordable, one pill, once daily potent antiretroviral regimens with minimal toxicities or drug interactions and high barriers to resistance are available in resource limited settings.

The Treatment 2.0 strategy has defined the optimal target product profile for simplified, safe and effective ARV drug regimens. Achieving this ideal regimen over the next 10 years will require intensified, targeted research and development, reduced time from research to market, optimization of currently available drugs, and the development of new drugs and therapeutic classes [13,14].

Initiatives launched, or supported, by WHO over the last 2 years related to treatment optimization include the Conference on Antiretroviral Drug Optimization (CADO), a meeting on the short-term priorities for ARV drug optimization and two meetings convened by WHO on the Strategic Use of Antiretrovirals for Treatment and Prevention (SUFA).

In 2010, CADO was convened by the Clinton Health Access Initiative (CHAI) in collaboration with Johns Hopkins University and the Bill and Melinda Gates Foundation. The conference brought together process chemists, clinical pharmacologists, pharmaceutical scientists, physicians, pharmacists, community, regulatory specialists, implementers and normative agencies to explore strategies for the reduction of antiretroviral drug prices without compromising efficacy [15▪▪]. Cost-saving approaches identified at the conference included: alternative sources of raw materials to generate market competition and drive down cost, the use of novel drug formulation technology, drugs with improved bioavailability (permitting dose reduction), drugs with extended shelf-life, studies to reduce the approved doses of current ARVs and the wider use of generic drugs and fixed-dose combinations (FDCs).

In April 2011, WHO, with the support of the Pangaea Global AIDS Foundation, convened a meeting to establish short-term priorities for the optimization of first-line and second-line ARV regimens [16]. On the basis of efficacy and toxicity, available compounds and the preferred first-line options in the 2010 WHO ART adult guidelines, meeting participants recommended the prioritization of the FDC of tenofovir–lamivudine (or emtricitabine) and efavirenz in first-line and atazanavir/ritonavir (ATV/r) as a heat stable FDC combined with a backbone of two nucleoside reverse transcriptase inhibitors (NRTIs) in second-line therapy [16]. With respect to pediatric ART, it was proposed to move away from liquid formulations, sprinkles, heat stable tablets and scored adult strength dispersible formulations were prioritized.

WHO convened two multidisciplinary consultations on the Strategic Use of Antiretrovirals for Treatment and Prevention (SUFA 1 and SUFA 2) in November 2011 and May 2012 [10▪▪,17]. SUFA 1 endorsed a roadmap and architecture for the development of global consolidated guidelines to be launched in 2013, which would include an expansion of the scope to address clinical, operational and programmatic guidance, a consolidation of guidance for different populations (infants, children, adolescents, adults, pregnant women, older adults, key populations) and of interventions (treatment and prevention, treatment of major co-infections). SUFA 2 addressed operational and programmatic issues related to the development of consolidated ARV guidelines. Six themes were addressed: strategic and programmatic decision-making processes in countries; modeling of epidemiology, costs and impact; ethics, equity and human rights; health systems requirements; policy formulation and prioritization; and interventions and resources.

One pill, once-daily formulations suitable for most populations have the potential to reduce drug and program costs, improve adherence and treatment success, simplify procurement and reduce risk of drug stock outs. In mid-2012, WHO released three technical updates in support of the one pill once daily principle. The first technical update provides a balanced assessment of the clinical and programmatic issues relating to the safety of efavirenz (EFV) in pregnancy. Early data from animal studies and case reports led to concerns about the safety of efavirenz in pregnancy, with the consequence that women of childbearing age and in early pregnancy were not initiated on efavirenz, whereas women who became pregnant on EFV were being switched to nevirapine and in some instances pregnancy was terminated. Programmatically, this results in increased complexity and cost due to the need to stock multiple regimens. On the basis of the available data and a public health perspective, this technical update supports the use of efavirenz to optimize and simplify first-line treatment, including among pregnant women and those of reproductive age [18▪▪].

The second technical update provided guidance to countries, programs and manufacturers that, despite limited direct comparisons, the available data support the clinical and programmatic interchangeability of 3TC and FTC [19]. This has important cost saving implications in the optimization of both first-line and second-line regimens. The lowest 2011 generic price for FTC was US$=61 per year compared with US$24 per year for 3TC [20]. In May 2012, the ceiling price from CHAI for tenofovir/FTC was US$97 per year compared with US$ 70 per year for tenofovir/3TC [21].

Finally, guidance to countries on the use of tenofovir for the treatment of children and adolescents with HIV was provided [22]. Being able to use tenofovir in children and adolescents would harmonize tenofovir-containing pediatric and adult regimens and pave the way for a one pill once daily pediatric FDC. The US Food and Drug Administration has approved tenofovir for use in adolescents and children in the USA above the age of 2 years. In this context, monitoring for tenofovir toxicity (relating to concerns about decreased bone mineral density and glomerular and renal tubular dysfunction) is possible. However, such monitoring is problematic in resource limited settings. This technical update concluded that tenofovir is efficacious in children and adolescents aged 2–18 years but cautioned that the benefits need to be weighed against the potential risk of toxicity and that long-term pharmacovigilance is needed as tenofovir is rolled out for children and adolescents.


Goal: a package of simple, affordable, reliable, quality assured point-of-care (POC) and other simplified diagnostics is available and accessible.

WHO is working to standardize performance and quality requirements, increase research and development, and reduce barriers to bring new diagnostics tools to market [13]. WHO and UNITAID (Tous Unis pour Aider)/IDPF (International Drug Purchase Facility) are working with technical experts to identify the ideal package of diagnostics and the required regulatory processes to bring these to market. UNITAID has reviewed diagnostic technologies based on the WHO assured criteria: affordable, sensitive, specific, user friendly, robust and rapid, equipment free, and deliverable [23▪]. WHO has identified the technologies that need be deployed now, and products that need to be developed in the short, medium and long term to promote competition and reduce prices.

Globally, less than 40% of people living with HIV know their serologic status [11]. Increased deployment of HIV rapid tests and novel approaches to delivering them, including home-based testing and community mobile testing, are being rolled out to bring testing and linkages to care into communities [23▪,24▪,25]. A focus of the work is POC CD4 cell count testing as a way to link HIV testing to eligibility assessment for initiation of ART. The technology is available and is being adopted, with field assessments showing a benefit in terms of reduced patient attrition and improved time to ART initiation [26]. The first generation technologies are device based and need an electricity connection or battery/solar power. New technology is being developed which aims to be device free, single use and disposable.

There is increasing evidence to support the use of viral load as a preferred method of monitoring the success or failure of ART [27▪,28,29]. WHO has called for expanded access to viral load testing to improve the early detection of treatment failure, reduce inappropriate switching to second-line ART, and preserve second-line treatment options [30]. Access to viral load testing is limited in most resource-limited countries (exceptions include South Africa, Thailand and Brazil). Simplified viral load platforms and assays are in development, at least one of which may come to market in 2012 [23▪].

In December 2010, WHO endorsed automated nucleic acid amplification test technology for the detection of tuberculosis (TB) and rifampin resistance. This technology is available in the form of the self-contained, cartridge-based GeneXpert MTB/RIF (Cepheid, Sunnyvale, California, USA). In addition to cartridges for TB and rifampicin resistance, cartridges for the Xpert device are available for detecting other pathogens, including Chlamydia, Neisseria gonorrhoeae and multidrug-resistant Staphylococcus aureus. In collaboration between the Foundation for Innovative New Diagnostics, the manufacturer of GeneXpert, is developing a cartridge to measure HIV viral load [31].

The use of dried blood spots (DBS) for collection and transport of specimens to a central laboratory has become standard of care in many early infant diagnosis programs. There is good correlation between plasma and DBS viral load and, while POC viral load is awaited, DBS samples can be collected in the clinic and sent to a central laboratory for vial load estimation [32]. Finally, there is a need for improved, simpler technologies to monitor ART adverse events and to monitor the emergence of population level drug resistance.

Reducing costs

Goal: High quality HIV care and treatment programs are available at the lowest possible cost with optimal efficiency.

UNAIDS has estimated that the cost of putting 15 million people on ART by 2015 will be US$22–24 billion [33]. HIV programs are already under enormous financial pressure. While more resources are needed from donor countries and those countries most affected by the epidemic, efficiencies need to be found which can drive down costs without compromising quality. Given the global financial crisis and competing health priorities, advocacy is needed to demonstrate that increasing investments in expanded ART and preexposure prophylaxis of HIV acquisition (PrEP) will result in long-term public health, economic and development benefits. Modeling indicates that increasing coverage of ART would be cost effective in the short term and could even be cost saving in the longer term [10▪▪]. Commodity costs can be reduced by pooled procurement and simplified manufacturing processes, and programs can deliver more services to more people through task shifting, integration of HIV services into primary care and other public health programmers, and expanding the role of communities in service delivery [13]. As part of ongoing work to reduce costs, UNDP, UNAIDS and WHO have released guidance on policy options for countries in employing trade-related aspects of intellectual property rights (TRIPS) flexibilities to ensure that patents do not hinder access to affordable medicines (UNDP/UNAIDS. The Potential Impact of Free Trade Agreements on Public Health, Geneva May, 2012 [34].

Community mobilization

Goal: people living with HIV and key populations are fully involved in the demand creation, planning, delivery and evaluation of quality assured, rights based HIV care and treatment programs.

Partnerships between communities, HIV programs and health workers serve to increase access, improve adherence, retention, efficiency and sustainability, and reduce stigma and discrimination. In March 2012, WHO and the Ministry of Health and Child Welfare of Zimbabwe, with the support of the Pangaea Global AIDS Foundation, cohosted a consultation on Optimizing HIV treatment access and retention in care: linking community level interventions with healthcare delivery systems. The goals of the meeting were to consult community organizations, networks of people living with HIV and civil society, and to review best practice of community service delivery models and to inform the service delivery component of the 2013 WHO consolidated ARV guidelines. Key recommendations from the meeting were the need to estimate the costs of community mobilization and provide sustainable funding streams to support community based organizations and networks working in the roll-out and scale-up of Treatment 2.0. Launched at the 2012 International AIDS Conference, the Robert Carr Civil Society Networks Fund aims to provide secure funding flows for civil society networks. The Carr Fund is expected to raise US$21 million in its first 3 years to support global and regional civil society networks (

A similar consultation was held in Bangkok, Thailand, in September 2012, with the aim of identifying the needs, challenges and best practices of providing services to key populations in low and concentrated epidemics, with the participation of a wide range of community-based organization and networks.

Adapting delivery systems

Goal: HIV care and treatment programs are decentralized and appropriately integrated with other health services, with increased community engagement and improved retention in care.

Less than 30% of people diagnosed with HIV infection in resource limited settings receive the full cascade of care, from HIV testing through to initiation of ART and long-term retention in care [35▪▪,36]. Substantial attrition and mortality follow HIV diagnosis and, in some settings, less than half of those eligible for ART initiate it within 12 months [37]. Under the Treatment 2.0 pillars of adapting service delivery and community mobilization, WHO is developing comprehensive guidance on the role of decentralization and integration of HIV services in improving access to and retention in ART care [38].

Normative guidance

Current WHO HIV treatment guidelines articulated evidence-based recommendations for HIV prevention, diagnosis, care and treatment. The new consolidated ARV guidelines that will be issued in 2013 will include programmatic and service delivery recommendations to inform countries not only of what to do but also how to do it and to guide prioritization and allocate decisions. The consolidated guidelines will address HIV during the life course (pregnant women, infants, children, adolescents, adults, older adults), include guidance for key affected populations, and address priority comorbidities [10▪▪]. In the lead up to 2013, support to countries has been provided in a series of targeted guidelines, and programmatic and technical updates. (Fig. 4)

WHO Treatment 2.0 publications.

Treatment 2.0 in action

An increasing number of countries and regions are adopting the Treatment 2.0 framework for their national plans. One example is Vietnam, where the HIV epidemic is concentrated amongst key populations at higher risk of HIV exposure, that is, people who inject drugs, female sex workers and MSM. Sentinel surveillance in 2010 found a prevalence of 17.2% among people who inject drugs, 4.6% among female sex workers and 0.26% amongst antenatal women. The Vietnamese Administration of HIV/AIDS Control, with support from the Joint United Nations Team on HIV, international partners and donors, has initiated a Treatment 2.0 pilot program, making Vietnam one of the first countries to adapt the principles of Treatment 2.0 to the local epidemic [39▪]. The pilot aims to increase the CD4 cell count at which most people in Vietnam initiate ART from the current norm of less than 100 cells/μl, phase out stavudine as recommended by WHO, and institute HIV rapid testing for key populations. Community mobilization is the fundamental component of the pilot, with decentralization of HIV services for isolated communities in the north of the country, integration of HIV testing and ART delivery with commune level services for tuberculosis, methadone maintenance treatment, and antenatal care, and efforts to reduce stigma and discrimination. Success of the pilot will require engagement of multiple stakeholders to move away from the current model of centralized HIV service delivery [39▪].

Another example is given by a recent publication by the Pan American Health Organization (PAHO) titled Antiretroviral Treatment in the Spotlight: 2012 A Public Health Analysis in Latin America and the Caribbean [40]. At the end of 2010, 521 000 people were receiving ART in Latin America and the Caribbean, with a regional ART coverage of approximately 63%. The objective of the report was to critically evaluate ART programs, assessing their strengths and weaknesses to guide the application of the principles of Treatment 2.0 in Latin America and the Caribbean. With 12 different adult first-line regimens and 15 s line regimens being employed in countries in the region, the potential for optimization is significant. In 2011, 14 out of 26 countries reported at least one stock-out episode, 92 of which averaged 40 days. Eleven countries, mostly from the Caribbean region, were almost 100% dependent on external funding for ART. Key recommendations in the report were to simplify regimens, reduce stock-outs and foreign donor dependency, increase HIV testing and retention in treatment, and strengthen prevention. This is the first in a series in which PAHO will monitor regional progress towards achieving the goals of Treatment 2.0, universal access and the Millennium Development Goals.


In 2011, more than 8 million people living with HIV in low-income and middle-income countries were receiving ART, a 20% increase since 2010. To sustain the momentum, affordable and sustainable mechanisms to foster pharmaceutical and diagnostics innovation need to be pursued, TRIPS agreement flexibilities need to be maximized to ensure more equitable pricing for essential drugs and Treatment 2.0 needs to evolve with the full involvement of people living with HIV and affected communities [41]. In addition to sustained support from donor nations, local solutions need to explore diversified funding sources and reduced dependency on imported commodities [42]. To this end, WHO will work with regional and national partners to support the integration of the Treatment 2.0 framework into national responses.


Bill and Melinda Gates Foundation.

Chris Duncombe is employed by the Bill and Melinda Gates Foundation.

Conflicts of interest

There are no conflicts of interest.


Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 75).


1. Abuja Declaration on HIV/AIDS, tuberculosis and other related infectious diseases 2001. Available from: http:// [Accessed 12 July 2012]
2. Africa Public Health. Info and Africa Health HaSDIS. 2012 Multi year Health Financing Trends Analysis and 2012 Health Financing Scorecard. 2012 [Accessed 12 July 2012].
3▪. WHO. The Abuja Declaration: Ten Years On. 2011 [Accessed 12 July 2012].

This publication highlights both the of importance of health goal setting and the difficulties that the global community is now facing both domestically and in terms of international assistance in meeting such goals.

4. OECD. Development: Aid to developing countries falls because of global recession. 2012 http:// [Accessed 10 July 2012].
5. OECD. Outlook on aid survey on donors’ forward spending plans 2012–2015. 2012 [Accessed 10 July 2012].
6▪▪. UNAIDS. Together we will end AIDS. 2012 [Accessed 29 July 2012].

Released at the 19th International AIDS Conference in Washington DC, August 2012, this latest UNAIDS publication in support of the ‘getting to zero’ principle is richly illustrated and easy to read.

7. WHO. HIV Operational Plan 2012 – 2013: WHO's support to implement the Global Health Sector Strategy on HIV/AIDS. 2012 [Accessed 17 July 2012]
8. WHO. GLOBAL HIV/AIDS RESPONSE: Epidemic update and health sector progress towards Universal Access. Progress report 2011. http:// [Accessed 17 July 2012]
9. UNAIDS. Political Declaration on HIV and AIDS: Intensifying Our Efforts to Eliminate HIV and AIDS. [Accessed 17 July 2012].
10▪▪. WHO. The strategic use of antiretrovirals to help end the HIV epidemic. 2012 [Accessed 16 July 2012]

This discussion study is the latest in a series of publications from WHO and was prepared for the 19th International AIDS Conference in Washington DC, August 2012. It highlights key issues that confront the global community, policy makers and national programme planners in continuing ART scale-up and how ARVs could contribute to eventually ending the HIV epidemic.

11. WHO. WHO Global health sector strategy on HIV/AIDS 2011-2015. 2011; http:// [Accessed 16 July 2012]
12. UNAIDS. UNAIDS 2011–2015 Strategy: Getting to Zero. 2010 [Accessed 10 July 2012].
13. WHO. The Treatment 2.0 framework for action: catalysing the next phase of treatment, care and support. 2011 [Accessed 17 July 2012].
14. Sidibe M. Antiretrovirals for prevention: realizing the potential. closing commentary by the executive director of UNAIDS. Curr HIV Res 2011; 9:470–472.
15▪▪. Crawford KW, Ripin DH, Levin AD. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost efficient delivery in resource-limited settings: a consensus statement. Lancet Infect Dis 2012; 12:550–560.

This report from the ground breaking CADO meeting on optimizing antiretroviral drugs articulates the consensus priority research agenda which is now being implemented in support of Treatment 2.0. .

16. WHO. Short-Term Priorities for Antiretroviral Drug Optimization Meeting Report. 2011 [Accessed 15 July 2012].
17. WHO. Strategic Use of Antiretrovirals for the Treatment and Prevention of HIV Infection; Report of a WHO technical consultation 2011 http:// [Accessed 15 July 2012]
18▪▪. WHO. Technical update on treatment optimization. Use of efavirenz during pregnancy: a public health perspective June 2012. 2012 [Accessed 16 July 2012].

One of a series of three policy and practice changing technical updates released by WHO in 2012 as a prelude to the 2013 consolidated guidelines

19. WHO. Technical update on treatment optimization: Pharmacological equivalence and clinical interchangeability of lamivudine and emtricitabine: a review of current literature. 2012 [Accessed 17 July 2012].
20. Medecines Sans Frontières. Untangling the Web Of Antiretroviral Price Reductions14th Edition July 2011. 2011 [Accessed 17 July 2012].
21. Initiative CHA. Antiretroviral (ARV) Ceiling Price List. 2012 [Accessed 17 July 2012].
22. WHO. Technical update on treatment optimization: Use of tenofovir in HIV-infected children and adolescents: a public health perspective. 2012 [Accessed 17 July 2012].
23▪. UNITAID. HIV/AIDS diagnostic technology landscape. 2nd edition 2012; [Accessed 18 July 2012]

An excellent and detailed overview UNITAID on the diagnostics pipeline, complete with projected timelines for the introduction of new technologies such as point of care viral load testing.

24▪. Van Rooyen H. High Testing Uptake and Linkages to HIV Treatment through Home-based HIV Counseling and Testing and Facilitated Referral: KwaZulu-Natal, South Africa [abstract]. In: 12th conference on retroviruses and opportunistic infections; Seattle 2012.

This conference presentation describes an innovative method of household community based HIV testing.

25. Molesworth AM, Ndhlovu R, Banda E, et al. High accuracy of home-based community rapid HIV testing in rural Malawi. J Acquir Immune Defic Syndr 2010; 55:625–630.Epub 2011/09/22..
26. Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 2011; 378:1572–1579.
27▪. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23–31.

Project Accept is ground breaking community testing and linkages to care program in African and Thailand.

28. Alvarez-Uria G, Naik PK, Pakam R, Midde M. Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting. Trop Med Int Health 2012; 17:1152–1155.
29. Hamers RL, Sawyer AW, Tuohy M, Stevens WS, de Wit TF, Hill AM, et al. Cost–effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 2012; 26:1663–1672.
30. WHO. Antiretroviral therapy for HIV infection in adults and adolescents; Recommendations for a public health approach 2010 revision. 2010 [Accessed 20 July 2012]
31. Foundation for Innovative New Diagnostics. [Accessed 20 July 2012].
32. Rottinghaus EK, Ugbena R, Diallo K, et al. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy. Clin Infect Dis 2012; 54:1187–1195.
33. UNAIDS. Inaugural Global Scientific Strategy Towards an HIV Cure launched ahead of the XIX International AIDS Conference in Washington DC. 2012 [Accessed 29 July 2012].
34. UNAIDS, UNCTAD, WHO, UNDP. Using TRIPS flexibilities to improve access to HIV treatment: Policy brief. 2006 [Accessed 19 July 2102].
35▪▪. 35Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011; 8:e1001056.

HIV testing and linkages to prevention, care and treatment and retention is an important topic as this and other systematic reviews reveal the extent of the problem of loss-to-follow up as people pass through the cascade of care.

36. Meta-analysis of Linkage to Care from HIV Diagnosis to Start of ART: Sub-Saharan Africa 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA March 5–8 2012. Poster abstract #1143.
37. Burtle D, Welfare W, Elden S, et al. Introduction and evaluation of a ’pre-ART care’ service in Swaziland: an operational research study. BMJ open 2012; 2:e000195.
38. WHO. Retention in HIV programmes: defining the challenges and identifying solutions. [Accessed 24 July 2012]
39▪. Duc Duong Bui FM, Thi Nhan Do, Masaya Kato, et al. Treatment 2.0 Pilot in Vietnam: early progress and challenges. World J AIDS 2012; 2(2).

This article describes progress and challenges in one of the first Treatment 2.0 pilot projects.

40. Organization TPAH. Antiretroviral Treatment in the Spotlight: 2012 A Public Health Analysis in Latin America and the Caribbean. 2012 [Accessed 24 July 2012]
41. Orsi F, d’Almeida C. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries. Curr Opin HIV AIDS 2010; 5:237–241.
42. UNAIDS. AIDS Dependency Crisis: Sourcing African Solutions. 2012 [Accessed 14 July 2012]

antiretroviral therapy; cost–effectiveness; HIV; Treatment 2.0

© 2013 Lippincott Williams & Wilkins, Inc.